St. Luke's Medical Center – Quezon City is a hospital in Quezon City, Metro Manila, Philippines. Forming as a part of St. Luke's Medical Center group of hospitals, it was founded in 1903 by the American ...

There are 650 beds in St. Luke's Medical Center.

During the past decade, St. Luke's Medical Center conducted 34 clinical trials. In the 10-year time frame, 34 clinical trials started and 32 clinical trials were completed, i.e. on average, 94.1% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 16 clinical trials were completed. i.e. 133.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "St. Luke's Medical Center" #1 sponsor was "Pfizer" with 8 trials, followed by "Allergan" with 7 trials sponsored, "Pfizer's Upjohn has merged with Mylan to form Viatris Inc." with 4 trials sponsored, "Boehringer Ingelheim" with 3 trials sponsored and "Hoffmann-La Roche" with 3 trials sponsored. Other sponsors include 32 different institutions and companies that sponsored additional 39 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "St. Luke's Medical Center" #1 collaborator was "Allergan" with 1 trials as a collaborator, "Baguio General Hospital and Medical Center, Philippines" with 1 trials as a collaborator, "Biomedical Advanced Research and Development Authority" with 1 trials as a collaborator, "Chong Hua Hospital, Philippines" with 1 trials as a collaborator and "Chugai Pharmaceutical" with 1 trials as a collaborator. Other collaborators include 28 different institutions and companies that were collaborators in the rest 38 trials.

According to Clinical.Site data, the most researched conditions in "St. Luke's Medical Center" are "Gastroparesis" (4 trials), "Diabetes Mellitus" (3 trials), "Hepatocellular Carcinoma" (3 trials), "Rheumatoid Arthritis" (3 trials) and "Systemic Lupus Erythematosus" (3 trials). Many other conditions were trialed in "St. Luke's Medical Center" in a lesser frequency.

Most popular intervention types in "St. Luke's Medical Center" are "Drug" (50 trials), "Biological" (9 trials), "Device" (3 trials), "Other" (3 trials) and "Combination Product" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Carboplatin" (3 trials), "Paclitaxel" (3 trials), "Relamorelin" (3 trials) and "ATM-AVI" (2 trials). Other intervention names were less common.

The vast majority of trials in "St. Luke's Medical Center" are 60 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "St. Luke's Medical Center". undefined are not yet recruiting, 7 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 41 completed trials in St. Luke's Medical Center, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in St. Luke's Medical Center, 2 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 43 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 1 trials that are defined as “Not Applicable".

St. Luke's Medical Center has several departments that took part in Clinical trials: "St. Luke's Medical Center, Human Cancer Biobank Research Center" - 2 trials